2. Jawa-Huicheng to Exhibit at the 64th CIPM in Qingdao, May 20-22, 2024.

    23 May, 2024 ● Qingdao，China

    Jawa-Huicheng was an invited exhibitor at the 64th CIPM, which is praised by exhibitors as the best pharmaceutical machinery exhibition in the Asia-Pacific region, on May 20-22, 2024, in Qingdao. The booth of Jawa-Huicheng was in the International hall; and Jawa-Huicheng showed and shared industry-leading medical track and trace system construction, UDI one-stop solution and results of global serialization practices. During CIPM, Jawa-Huicheng discussed requirements with many new and existing clients; who fully affirmed Jawa-Huicheng's capabilities.

  2. China Launches National Pilot Program for Drug and Consumable Traceability Code Collection

    30 September, 2024

    In April of this year, the China National Healthcare Security Administration (NHSA) initiated a pilot program for collecting traceability codes for drugs and consumables covered by medical insurance. By the end of 2024, all 32 provincial-level medical insurance information platforms across China will fully implement the collection of these traceability codes.

    On September 30th, the NHSA issued a notice aimed at further enhancing the collection of traceability code information for medical insurance drugs and consumables. The notice outlined that the NHSA is developing a unified interface for drug and consumable manufacturers and distributors to upload traceability code information at the national level. This new system will allow for a one-time upload that can be used across the entire country, eliminating the need for separate uploads to each province.

  2. NMPA solicited opinions on the "Regulations on the Supervision and Administration of Export Drug Production (Draft for Comments)"

    28 February, 2025

    On February 9th 2025, the Comprehensive Department of the National Medical Products Administration once again publicly solicited opinions on the "Regulations on the Supervision and Administration of Export Drug Production (Draft for Comments)", aiming to strengthen the supervision and management of export drug production and promote drug export trade. Compared to the "Regulations on the Supervision and Administration of the Production of Exported Drugs (Draft for Comments)" released by the National Medical Products Administration on August 6, 2024, the newly released draft for comments has added chapters on "Entrusted Production of Exported Drugs" and "Export Drug Archives", and merged and adjusted some provisions.

    The Management Regulations stipulate that if a pharmaceutical production enterprise accepts an entrusted agreement to produce and export drugs, it shall directly sign an entrusted production contract and quality agreement with the commissioning party. Both parties shall implement the drug management laws and regulations of China and importing countries (regions), as well as the quality responsibilities of drug GMP, and fulfill the obligation of drug quality assurance. The storage and transportation process of exported drugs within the country shall comply with the relevant requirements of the drug quality management standards for drug storage and transportation, ensuring that the entire process of drug export can be traced.

    Source site：
    https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20250209132616126.html?3jfdxVGGVXFo=1742458791594

  2. On April 25, the 66th CIPM concluded successfully!

    25 April 2025 ● Chongqing, China

    At this year’s pharmaceutical machinery exhibition, Jawa-huicheng made a wonderful appearance with innovative solutions such as industry traceability system construction plans and digital intelligence for production management, attracting many new and old friends to the scene.